Welcome to our dedicated page for Biohaven news (Ticker: BHVN), a resource for investors and traders seeking the latest updates and insights on Biohaven stock.
Biohaven Ltd. develops clinical-stage biopharmaceutical programs across immunology, obesity, neuroscience and oncology. News about BHVN commonly centers on pipeline progress for Kv7 ion channel modulation in epilepsy, MoDE™ and TRAP™ extracellular protein degraders for immunological diseases, myostatin-activin pathway agents for neuromuscular and metabolic diseases, and antibody-drug conjugates in cancer.
Company updates also cover clinical trial enrollment and data presentations, scientific conference activity, regulatory interactions, quarterly financial results and capital-raising activity. Recurring program references include opakalim, taldefgrobep alfa, BHV-1300, BHV-1400, BHV-8000, BHV-1510 and BHV-1530.
Biohaven (NYSE: BHVN) and SK Biopharmaceuticals signed a strategic global licensing and collaboration agreement granting SK Biopharmaceuticals an exclusive worldwide license to Biohaven's Kv7 ion channel platform, led by opakalim (BHV-7000), a selective Kv7.2/7.3 activator in Phase 2/3 development for focal epilepsy.
According to Biohaven, the deal includes up to $795 million in upfront and milestone payments related to the Kv7 platform, $400 million in near-term cash ($350 million at closing and $50 million in 2027), and an additional $150 million in development and regulatory milestones, plus tiered royalties on global net sales of opakalim. SK Biopharmaceuticals will assume future Kv7 program costs, including up to $245 million of specified obligations to Knopp Biosciences, while leveraging its established epilepsy commercial infrastructure. Closing is subject to antitrust and other customary regulatory reviews.
Biohaven (NYSE: BHVN) and Yale University announced that the U.S. District Court for the District of Delaware entered judgment in their favor on August 24, 2026, in trade secret misappropriation and breach of contract litigation against Avilar Therapeutics and RA Capital Management.
The judgment, entered by Judge Jennifer L. Hall, formalizes a combined $4 million award, reflecting a jury verdict on July 24, 2026. According to Biohaven, the jury found that RA Capital and Avilar willfully and maliciously misappropriated a Yale trade secret related to the "MODA" targeted protein degradation platform, and that RA Capital separately breached a 2019 confidentiality agreement with Yale.
The Court awarded $2 million to Yale for RA Capital's contract breach, and $1 million each to Yale and Biohaven for trade secret misappropriation. The MODA platform, developed by Yale professor Dr. David Spiegel, had been licensed by Biohaven for development and commercialization. The judgment is subject to potential post-trial motions.
Biohaven (NYSE: BHVN) reported second quarter 2026 results and extensive pipeline progress. The company advanced its extracellular protein degrader portfolio, initiating a pivotal Phase 3 trial of BHV-1300 in Graves' disease after Phase 1b data showed >80% mean reductions in pathogenic TSHR-IgG1 and rapid thyroid hormone normalization, with favorable safety. Updated Phase 1b data for BHV-1400 in IgA nephropathy showed >60% Gd-IgA1 reduction within 48 hours and ~70% within one month, supporting a pivotal study targeted for 2H 2026.
Biohaven also highlighted durable seizure control and tolerability data for opakalim (BHV-7000) across multiple epilepsy types, with Phase 2/3 RISE3 topline results expected in 2H 2026. Cash and equivalents were $270.5 million at June 30, 2026; quarterly R&D expenses were $100.8 million and net loss was $137.3 million ($0.91 per share), both improved versus 2025.
Biohaven (NYSE: BHVN) has appointed technology investor John Yetimoglu to its Board of Directors, effective immediately, according to Biohaven. Yetimoglu is Founder and Chief Investment Officer of Infinitum, focused on semiconductors, videogaming and next‑generation AI application platforms, and serves on the board of AI inference company Groq.
He previously worked as a Morgan Stanley analyst covering technology and biotechnology and holds an economics degree from Columbia University. Biohaven said the appointment supports its strategy to expand AI, machine learning and advanced computational methods across discovery, translational science and clinical development, enhancing the Board’s oversight of data- and computation-driven drug development.
Biohaven (NYSE: BHVN) and Yale University announced that a federal jury in the U.S. District Court for the District of Delaware returned a verdict in their favor in trade secret misappropriation and breach of contract litigation against Avilar Therapeutics and RA Capital. The jury found that Avilar and RA Capital willfully and maliciously misappropriated a Yale trade secret related to the MODA targeted protein degradation platform, and that RA Capital separately breached a 2019 confidentiality agreement with Yale. According to Biohaven, the jury awarded a total of $4 million in damages: $2 million to Yale for breach of contract, and $1 million each to Yale and Biohaven for trade secret misappropriation.
Biohaven (NYSE: BHVN) will present new Phase 1 data on BHV-1530, its first-in-class FGFR3-directed antibody-drug conjugate with a proprietary TopoIx payload, at the ESMO Congress 2026 in Madrid on October 23-27, including abstract 1019P scheduled for October 23, 15:15-16:00.
According to Biohaven, early dose-escalation results in advanced solid tumors show tumor reductions and confirmed partial responses in heavily pretreated patients with FGFR3-altered and wild-type overexpressing tumors, alongside a favorable safety profile with no dose-limiting or FGFR inhibitor–class toxicities observed to date. BHV-1530 is designed to target FGFR3 regardless of alteration status, potentially reaching a broader urothelial cancer population than FGFR tyrosine kinase inhibitors. Biohaven also announced a new clinical supply agreement with Regeneron to evaluate BHV-1530 with cemiplimab (Libtayo), expanding on their existing BHV-1510 ADC collaboration.
Biohaven (NYSE:BHVN) announced scientific leadership transitions effective July 13, 2026. David Pirman, Ph.D. is promoted to Executive Vice President and Head of Discovery, leading internal drug discovery. Bruce Car, Ph.D. retires as Chief Scientific Officer and becomes part-time Chief Innovation Officer, focusing on external collaborations, including assets under the Bexorg partnership. Warren Volles, General Counsel and Chief Legal Officer, is also designated an executive officer.
Biohaven (NYSE:BHVN) completed enrollment in RISE3, a pivotal Phase 2/3 randomized, double-blind, placebo-controlled study of opakalim, a selective Kv7.2/7.3 activator, for refractory focal epilepsy. Top-line results are expected in 2H 2026.
In the focal epilepsy open-label extension, 54% on opakalim 75 mg once daily achieved ≥50% seizure reduction over any six consecutive months (n>100), with low rates of nervous system adverse events (5% dizziness, 4% fatigue) and ~95% double-blind completion and rollover rates.
Biohaven (NYSE:BHVN) enrolled the first patient in its pivotal Phase 3 trial of BHV-1300 for Graves' disease, the first MoDE extracellular protein degrader in a pivotal study. BHV-1300 targets disease-driving TSHR-IgG1 autoantibodies, not the thyroid gland.
Phase 1b data showed >80% TSHR autoantibody reduction, rapid free T4/T3 normalization, symptom improvements, preservation of other immunoglobulins, and favorable tolerability. The randomized, double-blind, placebo-controlled trial (≈300 adults) assesses restoration of normal thyroid function at 26 weeks without antithyroid drugs, using a self-administered subcutaneous autoinjector.
Biohaven (NYSE:BHVN) began first-in-human dosing of BHV-8100, an oral, brain-penetrant PKM2 modulator targeting metabolic restoration and immunomodulation. The ongoing Phase 1 study in healthy participants shows preliminary pharmacokinetics consistent with convenient once-daily dosing and a well tolerated profile at projected therapeutic exposures.
Preclinical BrainEx data in ex-vivo human brains demonstrated excellent blood-brain barrier penetration, up to 3-fold improvement in cerebral glucose utilization and lactate production, and preferential metabolic rescue in Alzheimer's disease donor brains versus controls, supporting development across neurodegenerative, neuroinflammatory and retinal disease indications.